Prevention and Management of Bleeding Episodes in Patients with Congenital Hemophilia A and High Titer Inhibitors: Expert Opinion Summary

A CE Certified Online Activity

Management of patients with congenital hemophilia A relies on the replacement of the specific coagulation factor to treat and prevent bleeding episodes. The development of inhibitors against factor VIII is a severe complication of replacement therapy. Inhibitors increase morbidity by decreasing response to standard therapy, making bleeding episodes more difficult to control. In patients with high-titer inhibitors, hemostasis is traditionally achieved by the administration of bypassing agents. The goal of immune tolerance induction is to eradicate the inhibitor so that patients can be treated again with factor replacement therapy. This educational activity will review risk factors for developing inhibitors, discuss treatment strategies for the management of acute bleeding episodes and the prevention of bleeding episodes, and summarize current approaches for immune tolerance induction.

Available until June 30, 2011.
Physicians: 1.0 AMA PRA Category 1 Credit^™
Nurses: 1.0 contact hour

This activity is co-provided by SCEPTER^™, EduPro Resources LLC, and Quintiles Medical Education.